Business Advisors

Geert Cauwenbergh, Ph.D.

Dr. Cauwenbergh was the founder of Barrier Therapeutics, a biopharmaceutical company, and Phases123, a company focused on health care technology platforms and emerging health care companies. Mr. Cauwenbergh served as Global Vice President of Research and Development for Johnson & Johnson Consumer Companies Worldwide. Until recently he was the CEO and chairman of RHEI Pharmaceuticals, a company that in-licenses western pharmaceutical products for the Chinese and SE Asian markets. He is currently the chairman of the Board of BioNJ, the industry organization for biotechnology in New Jersey, and executive chairman of ECI Biotech, a leader in point of care diagnostic research and development.

Arthur Klausner

Mr. Klausner is a life sciences venture capitalist with more than 18 years of experience at Domain Associates and Pappas Ventures. Mr. Klausner has been a board member at Santarus, X-Ceptor, Altea Therapeutics, CeNeRx BioPharma, Gentis and Syndax Pharmaceuticals. He currently serves on the Board of Directors of Neurotez, a privately held biotherapeutics company focused on Alzheimer’s disease.

Scott Pallais

Mr. Pallais is an experienced pharmaceutical executive who worked in the pharmaceutical industry for Marion Laboratories in sales, marketing and medical education. After leaving Marion Laboratories he and his wife started a medical education company, Armand Scott, Inc., providing targeted, innovative educational products and services for clients in the pharmaceutical, biotechnology, medical devices, and managed care industries. In 2000, Mr. Pallais sold Armand Scott and now heads Sentinel Hydrosolutions, LLC., a technology company focusing on water security.

Joseph C. Sanginiti

Mr. Sanginiti spent 28 successful years within several fortune 500 organizations including 20 years working in the pharmacy benefit management industry as a senior executive of Express Scripts, a fortune 100 company. His experiences as Vice President and General Manager of Pharmacy Operations helps him bring to Edge Therapeutics a strong background in finance, operational management, leadership, and contract negotiations. More recently, Mr. Sanginiti started his own company, Asher Investments, LLC, where he is investing in early startup companies and serving on a number of Board of Directors.

Jordan Warshafsky

Mr. Warshafsky has more than 25 years of experience within the pharma, biotech, and medical device sectors of the Life Sciences industry. He has held corporate and division level leadership positions in business development, global marketing, and strategic planning. Prior to joining as a Partner of Ashton Tweed, Mr. Warshafsky served as President and Director of TYRX, Inc., a biotechnology company specializing in polymer drug delivery. Before that, he served as the Vice President, Strategic Development for Integra Life Sciences, a maker of medical and biotech devices. He has also completed strategic acquisitions for public and private companies.